

SCHWEGMAN ■ LUNDBERG ■ WOESSNER ■ KLUTH
PATENT, TRADEMARK & COPYRIGHT ATTORNEYS
P.O. Box 2938
Minneapolis, MN 55402
Telephone (612) 373-6900 Facsimile (612) 339-3061

April 1, 2003

Time: 11:30 am
(Minneapolis, Minn.)

TO: Commissioner for Patents
Attn: Christopher H. Yaen
Patent Examining Corps
Facsimile Center
Washington, D.C. 20231

FROM: Ann S. Viksnins
OUR REF: 875.043US1
TELEPHONE: (612) 373-6961

FAX NUMBER (703) 746-7646

Document(s) Transmitted: Draft Amendment (5 pages)

Total pages of this transmission, including cover letter: 6 pgs
If you do NOT receive all of the pages described above, please telephone us at 612-373-6900, or fax us
at 612-339-3061.

In re. Patent Application of: Bevcrly L. Davidson et al.

Examiner: Christopher H. Yaen

Serial No.: 09/757,824

Group Art Unit: 1642

Filed: July 17, 1998

Docket No.: 875.043US1

Title: PTD MODIFIED PROTEINS

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

By: Ann S. Viksnins
Name: Ann S. Viksnins
Reg. No.: Reg. No. 37,748

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office
on the date shown below.

Ann S. Viksnins
Ann S. Viksnins

1 April 2003
Date of Transmission

S/N 09/757,824PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Beverly L. Davidson et al. Examiner: Christopher H. Yaen
Serial No.: 09/757,824 Group Art Unit: 1642
Filed: January 9, 2001 Docket: 875.043US1
Title: PTD MODIFIED PROTEINS

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116

Box AF
Commissioner for Patents
Washington, D.C. 20231

Applicant has reviewed the Office Action mailed on December 3, 2002. Please amend the above-identified patent application as follows.

This response is accompanied by a Petition, as well as the appropriate fee, to obtain a one-month extension of the period for responding to the Office Action, thereby moving the deadline for response from March 3, 2003 to April 3, 2003.

IN THE CLAIMS

1-33. [withdrawn]

34. [Currently Amended] A polypeptide comprising a non-denatured, soluble lysosomal enzyme, a naturally secreted protein, a nuclear protein, or a cytoplasmic protein operably linked to a PTD, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient, and wherein the polypeptide is biologically active. *supported?*

35. [cancelled] The polypeptide of claim 34, wherein the polypeptide is a lysosomal enzyme.

36. [Currently Amended] The polypeptide of claim 34, wherein the lysosomal enzyme polypeptide is a soluble lysosomal enzyme.

37. The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.